Angiotensin II regulation of vascular endothelial growth factor and receptors Flt-1 and KDR/Flk-1 in cyclosporine nephrotoxicity

Kidney International

Volumn 62, Issue 2, 2002, Pages 422-433

  Shihab, Fuad S ^a,b   Bennett, William M ^a,b   Isaac, Jorge ^a,b   Yi, Hong ^a,b   Andoh, Takeshi F ^a,b  

^a ARUP LABORATORIES   (United States)

^b Legacy Solid Organ and Cellular Transplantation Services   (United States)

Author keywords

Chronic nephrotoxicity; Enalapril; Fibrosis; Immunosuppression; Losartan; Macrophages; Matrix

Indexed keywords

ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIAL CELL GROWTH FACTOR; FLT1 PROTEIN, RAT; IMMUNOSUPPRESSIVE AGENT; LOSARTAN; LYMPHOKINE; SCLEROPROTEIN; SIGNAL PEPTIDE; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; ANGIOTENSIN; CREATININE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; MESSENGER RNA; NILVADIPINE; SODIUM CHLORIDE;

ANIMAL; ARTICLE; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG EFFECT; GENE EXPRESSION; GENETICS; KIDNEY DISEASE; MALE; METABOLISM; PATHOLOGY; RAT; SPRAGUE DAWLEY RAT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BLOOD PRESSURE; CELL INFILTRATION; CONTROLLED STUDY; CREATININE CLEARANCE; DOWN REGULATION; FEEDING; HISTOLOGY; MACROPHAGE; NEPHROTOXICITY; NONHUMAN; NORTHERN BLOTTING; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; RNA ANALYSIS; SODIUM DEPLETION; WESTERN BLOTTING;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; CYCLOSPORINE; DISEASE MODELS, ANIMAL; ENALAPRIL; ENDOTHELIAL GROWTH FACTORS; EXTRACELLULAR MATRIX PROTEINS; GENE EXPRESSION; IMMUNOSUPPRESSIVE AGENTS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY DISEASES; LOSARTAN; LYMPHOKINES; MALE; RATS; RATS, SPRAGUE-DAWLEY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0035991410     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2002.00452.x     Document Type: Article

References (41)

1. Molecular and biological properties of vascular endothelial growth factor
2. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells
3. Role of vascular endothelial growth factor in the regulation of angiogenesis
4. Role of vascular endothelial growth factor in the response to vessel injury
5. Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney
6. Cyclosporine nephropathy: Pathophysiology and clinical impact
7. Chronic cyclosporine nephropathy: The Achilles' heel of immunosuppressive therapy
8. Role of transforming growth factor-β1 in experimental chronic cyclosporine nephropathy
9. Expression of apoptosis regulatory genes in chronic cyclosporine nephrotoxicity favors apoptosis
10. Expression of vascular endothelial growth factor and its receptors Flt-1 and KDR/Flk-1 in chronic cyclosporine nephrotoxicity
11. Interaction of angiotensin II and mechanical stretch on vascular endothelial growth factor production by human mesangial cells
12. Vascular endothelial growth factor induces nephrogenesis and vasculogenesis
13. Vascular endothelial growth factor expression in human chronic renal allograft rejection
14. Angiotensin II in renal fibrosis: Should TGF-β rather than blood pressure be the therapeutic target
15. Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists
16. Renin-angiotensin system in chronic renal allograft dysfunction
17. Angiotensin II blockade decreases TGF-β1 and matrix proteins in cyclosporine nephropathy
18. Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle
19. Various rat adult tissues express only one major mRNA species from the glyceraldehyde-3-phosphate dehydrogenase multigenic family
20. Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril
21. Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells
22. Upregulation of vascular endothelial growth factor by angiotensin II in rat heart endothelial cells
23. Angiotensin II stimulates the synthesis and secretion of vascular permeability factor/vascular endothelial growth factor in human mesangial cells
24. Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hypermeability in experimental diabetes
25. OH H Angiotensin II-stimulated vascular endothelial growth factor expression in bovine retinal pericytes
26. A potential role for angiotensin II-induced vascular endothelial growth factor expression in the pathogenesis of diabetic nephropathy
27. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system
28. 2 receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation
29. Post-cyclosporine-mediated hypertension and nephropathy: Amelioration by vascular endothelial growth factor
30. Hypoxic induction of vascular endothelial growth factor (VEGF) in human epithelial cells is mediated by increases in mRNA stability
31. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia
32. Different signal transduction properties of KDR and Flt-1, two receptors for vascular endothelial growth factor
33. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR
34. Interaction of the Flt-1 tyrosine kinase receptor with the p85 subunit of phosphatidylinositol 3-kinase. Mapping of a novel site involved in binding
35. Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis
36. Systemic activation of the vascular endothelial growth factor receptor KDR/flk-1 selectively triggers endothelial cells with an angiogenic phenotype
37. Vascular endothelial growth factor receptors in human mesangium in vitro and in glomerular disease
38. Expression of vascular endothelial growth factor in renal vascular disease and renal allografts
39. Vascular endothelial growth factor activates MAP kinase and enhances collagen synthesis in human mesangial cells
40. Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells
41. Angiotensin II as a mediator of tubulointerstitial injury